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Orexin neurons originating in the perifornical and lateral hypothalamic area are
highly reactive to anxiogenic stimuli and have strong projections to anxiety and
panic-associated circuitry. Recent studies support a role for the orexin system
and in particular the orexin 1 receptor (OX1R) in coordinating an integrative stress
response. However, no selective OX1R antagonist has been systematically tested
in two preclinical models of using panicogenic stimuli that induce panic attack
in the majority of people with panic disorder, namely an acute hypercapnia-panic
provocation model and a model involving chronic inhibition of GABA synthesis in
the perifornical hypothalamic area followed by intravenous sodium lactate infusion.
Here we report on a novel brain penetrant, selective and high affinity OX1R
antagonist JNJ-54717793 (1S,2R,4R)-7-([(3-fluoro-2-pyrimidin-2-ylphenyl)carbonyl]-N-
[5-(trifluoromethyl)pyrazin-2-yl]-7-azabicyclo[2.2.1]heptan-2-amine). JNJ-54717793 is a
high affinity/potent OX1R antagonist and has an excellent selectivity profile including
50 fold versus the OX2R. Ex vivo receptor binding studies demonstrated that after oral
administration JNJ-54717793 crossed the blood brain barrier and occupied OX1Rs in
the rat brain. While JNJ-54717793 had minimal effect on spontaneous sleep in rats and
in wild-type mice, its administration in OX2R knockout mice, selectively promoted rapid
eye movement sleep, demonstrating target engagement and specific OX1R blockade.
JNJ-54717793 attenuated CO2 and sodium lactate induced panic-like behaviors and
cardiovascular responses without altering baseline locomotor or autonomic activity.
These data confirm that selective OX1R antagonism may represent a novel approach of
treating anxiety disorders, with no apparent sedative effects.
Keywords: orexin, hypocretin, panic, anxiety, hypercapnia
Frontiers in Pharmacology | www.frontiersin.org 1 June 2017 | Volume 8 | Article 357
fphar-08-00357 June 7, 2017 Time: 17:43 # 2
Bonaventure et al. Evaluation of JNJ-54717793 in Models of Panic
INTRODUCTION
Orexin neurons are located in the perifornical and lateral
hypothalamus of rodents (Peyron et al., 1998), and humans
(Thannickal et al., 2007). The role of orexins (OX-A and
OX-B) and orexin receptors (OX1R and OX2R) in complex
emotional behavior including innate anxiety and panic and fear
associated learning is emerging (Johnson et al., 2010; Boss and
Roch, 2015; Flores et al., 2015). For instance, optogenetically
stimulating orexin neurons in rats increases anxiety-like states
in anxiety-related neural circuits (Heydendael et al., 2013) as
well as stress hormone release and tachycardia (Bonnavion
et al., 2015). In addition, artificially increasing orexin-A levels
in the cerebrospinal fluid of rodents increases anxiety associated
behaviors (Suzuki et al., 2005), which is consistent with elevated
orexin levels being associated with increases in anxiety symptoms
in neuropsychiatric patients (Johnson et al., 2010). Severe anxiety
such as panic attacks are also more prevalent during the wake
phase (de Beurs et al., 1994) when orexin levels are at their highest
levels in humans (Mignot et al., 2002) and in rats (Desarnaud
et al., 2004).
Excitation of the perifornical hypothalamic area, which
contains particularly high concentration of orexin neurons,
produces robust flight and escape behaviors, and cardioexcitation
in rodents (Shekhar and DiMicco, 1987; Anderson and DiMicco,
1990; Shekhar et al., 1990; Soltis and DiMicco, 1992; Samuels
et al., 2002), and induces core symptoms of panic attacks in
humans [e.g., fear of dying, cardiorespiratory symptoms, and
thermal sensations (Rasche et al., 2006; Wilent et al., 2010,
2011)]. In orexin knockout mice, cardiovascular responses are
diminished following perifornical hypothalamic area stimulation
(Kuwaki et al., 2008). Panic disorder is characterized by recurrent
spontaneous panic attacks, which can be reliably induced with
interoceptive stimuli such as intravenous 0.5 M sodium lactate
and 5 min of 5–7% hypercapnic gas exposure, which do not
induce panic attacks in healthy controls (Pitts and McClure,
1967; Woods et al., 1988; Gorman et al., 1994). Exposing
healthy humans to higher concentrations of hypercapnic gas
(i.e., 20% CO2 inhalation) will also induce core features of
panic attacks (Forsyth et al., 2000). Collectively, these two panic
paradigms can be modeled in rats: (1) chronic disinhibition of
the perifornical hypothalamic area orexin region also produces
rats that are vulnerable to displaying panic-like responses
to interoceptive stimuli, such as sodium lactate (see review,
Johnson and Shekhar, 2012); and (2) exposing naïve rats to
20% hypercapnic gas exposure also induces panic-associated
responses. Both panic models, using stimuli that signal a
threatening internal body state change, activate OX neurons
in the perifornical hypothalamic area (Williams et al., 2007;
Johnson et al., 2010, 2012c,d) and increase panic associated
behaviors (e.g., flight like locomotion and anxiety in a social
interaction (SI) test and defensive burying test) and panic
associated dyspnea (Hickman et al., 2016) and cardioexcitation
(Johnson et al., 2010, 2012c,d, 2015). In these panic models,
silencing prepro orexin (sodium lactate only) or selective OX1R
antagonists attenuate panic-like responses to CO2 and sodium
lactate (Johnson et al., 2010, 2012c, 2015). Additionally, in
rats a selective OX1R antagonist blocks cellular responses in
panic and anxiety brain circuits (e.g., amygdala and dorsal
periaqueductal gray and sympathetic nuclei) post-administration
of a panicogenic drug (Johnson et al., 2012c), and in humans
recent imaging data indicate that a selective OX1R antagonist
produced a region-dependent inhibition of yohimbine-induced
activation in fronto-hippocampal regions as well as in several
key components of the extended amygdala (Gozzi et al.,
2013). The OX1R inhibition in the amygdala is consistent
with preclinical studies demonstrating that the OX system is
implicated in amygdala regulation of fear-associated learning
(Johnson et al., 2012a; Sears et al., 2013; Flores et al., 2014).
Overall, there is compelling evidence that overactivation of
the OX1R pathway is associated with hyper-excited or hyper-
active states; thus conceptually, a selective OX1R antagonist
might normalize overexcited networks without inducing sedation
(Bonaventure et al., 2015b). Based on these preclinical data,
we developed a selective OX1R antagonist with suitable drug-
like properties. A separate paper describes the new OX1R
antagonist JNJ-54717793 (Figure 1) synthesis, structure activity
relationship, pharmacokinetics in preclinical species (Shireman
et al., submitted).
Here, we report a comprehensive pharmacological
characterization of JNJ-54717793 and its evaluation in two
well-established models of panic provocation. In vitro affinity
and potency for the human and rat OX1R were determined by
radioligand binding and in vitro functional assays. In vivo target
engagement was measured after oral dosing of JNJ-54717793 in
rat brain using ex vivo receptor occupancy. We have recently
shown that while selective OX1R antagonism did not affect sleep-
wake states, additional pharmacological blockade of OX1R to
OX2R inhibition elicited a disinhibition of rapid eye movement
(REM) in rats and mice (Dugovic et al., 2014). Therefore, the
effect of the selective OX1R antagonist on sleep was tested in
OX2R knockout (KO) mice to demonstrate in vivo functional
target engagement.
FIGURE 1 | Chemical structure of JNJ-54717793
(1S,2R,4R)-7-([(3-fluoro-2-pyrimidin-2-ylphenyl)carbonyl]-N-[5-
(trifluoromethyl)pyrazin-2-yl]-7-azabicyclo[2.2.1]heptan-2-amine).
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MATERIALS AND METHODS
Chemicals
Almorexant, EMPA, GSK-1059865, SB-674042, and JNJ-
54717793 were synthetized at Janssen Research & Development,
LLC. Peptides were obtained from Bachem (Torrance, CA,
United States).
Animals
All animal procedures performed in this study were in
accordance with the Guide for Care and Use of Laboratory
Animals adopted by the US National Institutes of Health (NIH
Publication no. 80-23 revised 1996) and the guidelines of the
Institutional Animal Care and Use Committee. Animals were
housed under controlled conditions with a 12/12 h light/dark
schedule and temperature of 22 ± 2◦C. Food and water were
provided ad libitum. Experiments were performed after animals
had acclimated for at least 1 week unless stated otherwise.
In Vitro Radioligand Binding Assays
Human or rat OX1R binding was measured in competitive
radioligand binding assays using [3H]SB-674042 (1-(5-(2-fluoro
-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxa-
diazol-2-ylmethyl)-pyrrolidin-l-yl)-methanone) as a tracer
(4 nM, specific activity 35 Ci/mmol) as previously described
(Langmead et al., 2004). Cell membranes were prepared from
clonal CHO K1 cells transfected with the human OX1R or
clonal HEK-293 cells transfected with the rat OX1R. Dilutions
of test compounds were made in Dulbecco’s PBS from 10 mM
stocks dissolved in dimethyl sulfoxide. After a 60 min incubation
at room temperature, binding reactions were filtered. The
membranes were counted in a scintillation counter. Non-
specific binding was determined in the presence of 10 µM
almorexant. Affinities of compounds for the human OX2R were
measured by competitive radioligand binding using tritiated
N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-
amino]-N-pyridin-3-ylmethyl-acetamide (EMPA) (2 nM,
specific activity 27 Ci/mmol) (Malherbe et al., 2009). Cell
membranes were prepared from a stable pool of HEK-293 cells
transfected with the human OX2R. Non-specific binding was
determined with 10 µM almorexant.
The Ki of the test compounds was calculated based on non-
linear regression (one site competition) using Graphpad Prism.
The selectivity of JNJ-54717793 was evaluated in a large variety
of ion-channels, transporters and receptor-binding assays. These
assays were performed by Eurofins (Celles L’Evescault, France).
In Vitro Functional Assays (Calcium Mobilization
Assays)
Stably transfected CHO-K1 cells for the human OX1R or HEK-
293 cells for the rat OX1R were used for the in vitro functional
assays. The human OX2R functional assay used PFSK-1 cells
which are a human neuroectodermal cell line that innately
expresses the OX2R. Since the intracellular calcium response
is transient and not consistent with equilibrium assumptions,
the assays were performed by giving a standard, EC80 dose of
the OX agonist and calculating a pKB from inhibition of the
agonist response by a dose range of the antagonists. The cells
were plated in black 96 well tissue culture plates with clear
bottoms at 50,000 cells/well and grown overnight at 37◦C in 5%
carbon dioxide (CO2). Dilutions of the antagonist were prepared
in Hanks Balanced Salt Solution (HBSS) from 10 mM DMSO
stocks, while dilutions of OX peptides (OX-A for OX1R assays,
OX-B for OX2R assays) were prepared in HBSS + 0.1% bovine
serum albumin. On the day of the assay, a 2X dye-loading
solution (BD Calcium Assay Kit) was added to the cells and
incubated for 45 min at 37◦C in 5% CO2. Dilutions of the test
compounds were added and the cells were incubated at room
temperature for 15 min. The cell plate was then transferred to the
Molecular Devices Fluorometric Imaging Plate Reader (FLIPR)
Tetra instrument, which adds the OX agonist and monitors
changes in fluorescence which reflect intracellular calcium levels.
Results were calculated using GraphPad Prism (San Diego,
CA, United States) software. Raw data from the FLIPR Tetra
was exported as the difference between maximum and minimum
fluorescence observed for each well. A non-linear regression was
used to determine the agonist EC50 and antagonist IC50 for each
plate, then the antagonist KB was calculated according to Cheng
and Prusoff (Cheng and Prusoff, 1973).
Ex Vivo Receptor Occupancy Assay
Experiments were performed as previously described (Dugovic
et al., 2009) in male Sprague-Dawley rats (300–400 g, Charles
River Laboratories, San Diego, CA, United States). The animals
were euthanized using carbon dioxide and decapitated at
different time points after drug administration (n = 3 per time
point or dose regimen). Brains were rapidly frozen on powdered
dry ice and stored at −80◦C before sectioning. Plasma samples
were also collected for bioanalysis (LC–MS/MS). Twenty micron
thick tissue sections at the level of the tenia tecta were prepared
for autoradiography. OX1R radioligand binding autoradiography
was determined at room temperature with 5 nM [3H]SB-674042.
Sections were incubated for 10 min to minimize dissociation.
Non-specific binding was determined in the presence of 10 µM
SB-674042. Ex vivo receptor labeling was expressed as the
percentage of receptor labeling in corresponding brain areas
(i.e., tenia tecta) of vehicle-treated animals. The percentage of
receptor occupancy was plotted against time or dosage using
GraphPad Prism (GraphPad Software, San Diego, CA, United
States). Percentage of receptor occupancy was also plotted against
drug plasma or brain concentration. Pharmacokinetic parameters
were analyzed using a non-compartmental model using the
software package WinNonlin Version 4.0.1 (Pharsight, Palo Alto,
CA, United States).
Sleep Recording and Analysis in Rats and Mice
Sleep experiments were conducted in male Sprague-Dawley rats
(350–450 g, Harlan Laboratories, Livermore, CA, United States)
and in male C57Bl6 OX2R knockout (KO) and corresponding
wild-type mice (30–35 g, Charles River Laboratories, San Diego,
CA, United States) as described previously (Dugovic et al., 2009).
Animals were chronically implanted with telemetric devices
(Data Sciences International, St. Paul, MN, United States) for the
recording of electroencephalogram (EEG) and electromyogram
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(EMG) signals. Polysomnographic waveforms were analyzed per
10-s epoch and classified as wake, non-rapid eye movement
(NREM) or REM sleep by using the computer software program
SleepSign (Kissei Comtec, Nagano, Japan). For each experiment,
EEG and EMG signals were recorded for up to 6 h after
administration of the tested compounds. Analysis of sleep
parameters included latency to NREM sleep (defined as the time
interval to the first six consecutive NREM epochs) and REM sleep
(the first two consecutive REM epochs post-treatment), and the
duration of NREM and REM.
Results were averaged and expressed as mean ± SEM
in defined time intervals. To determine whether differences
were significant at a given interval, either paired Student’s
t-test or two-way analysis of variance (ANOVA) (interaction
time × treatment), repeated measures followed by Bonferroni
post hoc test was performed.
Normoxic, 20% CO2 Panic Provocation Model
Experiments were performed in male Sprague-Dawley rats
(300–350 g, Harlan Laboratory, Indianapolis, IN, United States).
Using CO2 (ProCO2) and O2 (ProO2) sensors in our enclosed
flow cages (12 inch width × 12 inch height × 24 inch length),
we have previously verified that O2 and CO2 concentrations
remain normal with atmospheric air infusion, and that only
the CO2 concentrations rapidly increase from <1 to 20% at
the 5 min time point for CO2 challenge (Johnson et al., 2005).
In a counter-balanced design (i.e., all rats received each drug
treatment with at least 48 h between treatments), rats were
systemically treated with a control vehicle or a selective OX1R
antagonist, and then placed into the chamber where atmospheric
air was being infused. All rats had infusions of the following:
(1) 5 min infusion of atmospheric gas (<1% CO2, 21% O2,
79% N2: Praxair, Inc.) for baseline measurements (∼45–60 min
post-treatment), then (2) either the control gas or experimental
normoxic, hypercarbic gas (20% CO2, 21% O2, 59% N2: Praxair)
for 5 min (note: for control rats the atmospheric gas was turned
off and back on again at the beginning and end of this infusion
to be identical to the manipulations for the hypercarbic gas
challenge), and finally (3) 5 min infusion of atmospheric gas.
Following exposure to hypercarbic and atmospheric air gasses,
rats were immediately placed in the open-field box for a 5 min
period then assessed in SI test for 5 min. The data reported
are changes in activity, expressed in 1 min bins, relative to the
average of the baseline measurement (t-5 to t-1 minute) from
each rat.
Sodium Lactate Panic Provocation Model
Experiments were performed in male Sprague-Dawley rats
(300–350 g, Harlan Laboratory, Indianapolis, IN, United States).
Prior to and during surgeries, rats were anesthetized with a
nose cone connected to an isoflurane system (MGX Research
Machine; Vetamic, Rossville, IN, United States). Radiotelemetry
probes [Cat. no. HD-S11, Data Sciences International, St. Paul,
MN, United States] were surgically implanted into the peritoneal
cavity and sutured to the muscle wall in order to assess general
motor activity. A pressure transducer was implanted into the
femoral artery to assess cardiovascular responses [i.e., mean
arterial blood pressure (MAP) and heart rate (HR)]. Rats were
also fitted with femoral venous catheters for 0.5 M i.v. sodium
lactate (NaLac) infusions, as previously described (Shekhar et al.,
1996). After 3–5 days of recovery, rats were anesthetized and 26
gauge T-shaped cannulae (Cat. no. 3260PG, Plastics One, Inc.,
Roanoake, VA, United States) were directed at cardio-excitatory
Perifornical hypothalamic area regions [(Shekhar and Keim,
1997) bregma: 1.2 mm posterior, +2.1 mm lateral, +9.1 mm
ventral and adjusted for approaching at a 10◦ angle toward the
midline with the stereotaxic incisor bar elevated 5 mm above the
interaural line] and cemented into place. The 22 gauge side arm
was then attached, via PE-60 tubing, to an osmotic minipump
(prefilled with 1-allyglycine solution chronically infused at
3.5 nmol/0.5 µl per hour) and sutured into place subcutaneously
at the nape of the neck (DURECT Corporation, Model no.
2002). Previous studies have determined that the dose of 1-
allyglycine utilized here reduces local GABA concentrations by
approximately 60% following unilateral infusions (Shekhar and
DiMicco, 1987; Abshire et al., 1988; Shekhar et al., 1996, 2006;
Shekhar and Keim, 1997).
Five days following 1-allyglycine infusion onset, in a
counterbalanced design and with 48 h between crossover, rats
were orally dosed with either JNJ-54717793 at 3, 10, or 30 mg/kg,
or vehicle as a control group 60 min prior to the 15 min 0.5 M
sodium lactate challenge. DSI DATAQUEST software was used
to monitor and record mean arterial pressure, HR, and motor
activity which were recorded continuously in freely moving
conscious rats and are expressed as a 20 min time course. The data
reported are changes in mean arterial blood pressure, HR, and
activity from the average of the baseline (t-5 to t-1) from each rat.
Baseline SI testing was done 7–8 days following radiotelemetry
surgery recovery, and repeated again 2–3 days later during drug
treatment crossover. On experimental drug testing days, the
SI test was performed 5 min after the offset of the sodium
lactate challenge with different partners each time. The SI box
dimension were 0.9 m long × 0.9 m wide × 0.3 m height. The
SI test is a validated test of experimental anxiety-like behavior
in rats that is sensitive to FDA approved treatments for anxiety
disorder symptom management that includes benzodiazepines
and selective serotonin reuptake inhibitors (SSRIs) (Sanders and
Shekhar, 1995; Shekhar and Katner, 1995). All behavioral tests
were digitally videorecorded with a camera above the box. The
“experimental” rat and an unfamiliar “partner” rat were both
allowed to individually habituate to the box for a 5 min period
24 h prior to each SI test. During the SI test, the two rats were
placed together in the center of the box, and the total duration
(sec) of non-aggressive physical contact (grooming, sniffing,
crawling over and under, etc.) initiated by the “experimental”
rat is quantified over a 5 min duration. A baseline SI test was
performed at least 72 h after i.v. catheterization, but prior to
osmotic minipump implantation. Another SI test was performed
5 days following minipump infusions and immediately following
saline or sodium lactate infusions. Video recorded sessions were
scored at a later time by Stephanie D Fitz, whom was blind to any
drug treatment.
Following experiments, all rats were anesthetized and
decapitated, their brains were removed, frozen, sectioned
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(30 µm) and stained with Neutral Red for determination of
injection cannulae placements.
Each dependent variable for assessment of behavior and
radiotelemetry data was respectively analyzed using a one way
ANOVA, or a one way ANOVA with repeated measures with
drug treatment as the main factor and time as repeated measures.
In the presence of significant main effects post hoc tests were
conducted using a parametric Fisher’s LSD test. Within subjects
time effects were also assessed using a Dunnett’s one way analysis
with the minute prior to the i.v infusion used as the control.
Statistical significance was accepted with p < 0.05. All statistical
analyses were carried out using SPSS 13.0 (SPSS, Inc., Chicago,
IL, United States) and all graphs were generated using SigmaPlot
2001 (SPSS, Inc., Chicago, IL, United States) or Graphpad Prizm
7 Software, Inc. for Windows.
RESULTS
JNJ-54717793 is a Selective High Affinity
OX1R Antagonist
The affinity of JNJ-54717793 for the human and rat OX1R
was determined by competitive radioligand binding using [3H]-
SB674042. To determine the selectivity ratio versus the OX2R, the
affinity of the compounds for the human OX2R was determined
by competitive radioligand binding using [3H]-EMPA as the
radioligand.
JNJ-54717793 showed high affinity binding to the human and
rat OX1R, with pKi values of 7.83 and 7.84 nM, respectively
(Table 1). The binding selectivity of JNJ-54717793 at the human
OX1R compared to the human OX2R was substantial (∼50 fold).
JNJ-54717793 was assayed by binding in a panel of 50
receptors, ion channels and transporters assays including
adenosine (A1, A2A, A3), adrenergic (α1, α2, α1), angiotensin
(AT1), dopamine (D1, D2), bradykinin (B2), cholecystokinin
(CCKA), galanin (GAL2), melatonin ML1), muscarinic (M1, M2,
M3), neurotensin (NT1), neurokinin (NK2, NK3), opiate
(µ, κ, δ), serotonin (5-HT1A, 5-HT1B, 5-HT2A, 5-HT3,
5-HT5A, 5-HT6, 5-HT7), somatostatin, vasopressin (V1a),
norepinephrine transporter, dopamine transporter and ion
channels (sodium, calcium, potassium, and chloride). JNJ-
54717793 at concentrations up to 10 µM had no significant
affinity for any receptor/transporter/ion channel (<50%
inhibition at 10 µM) other than the OX1R.
The functional antagonism of JNJ-54717793 for the human or
rat OX1R was determined by measuring changes in intracellular
TABLE 1 | In vitro binding affinities (pKi ) and in vitro functional potencies (pKb) of
JNJ-54717793 at the human and rat OX1R and OX2R.
Affinity (pKi) Potency (pKb)
hOX1R 7.83 ± 0.16 (12) 7.78 ± 0.31 (5)
rOX1R 7.84 ± 0.12 (17) 7.45 ± 0.20 (2)
hOX2R 6.14 ± 0.14 (16) 6.51 ± 0.24 (4)
The values are expressed as average ± SEM, and the number of triplicate
experiments is indicated between parentheses.
calcium in cell culture assays in response to an EC80 dose of
OX-A. Functional antagonism data, summarized in Table 1,
showed that the high affinity OX1R binding of JNJ-54717793 was
reflected in potent functional activity. The pKB values correlated
well with the pKi values for the human and rat OX1R. The
binding selectivity of JNJ-54717793 at the OX1R compared to the
OX2R was confirmed at the functional level (Table 1).
JNJ-54717793 Crosses the Blood Brain
Barrier and Occupies the OX1R in Rat
Brain after Systemic Administration
In vivo occupancy of the OX1R was assessed by ex vivo receptor
binding autoradiography of [3H]SB-674042 in rat brain tissue
sections at the level of the tenia tecta. Time-dependency and
dose-dependency were assessed after oral dosing (Figure 2).
FIGURE 2 | Ex vivo brain OX1R binding autoradiography by JNJ-54717793
measured in the tenia tecta (A) Duration of occupancy for JNJ-54717793
post-oral administration in rats (30 mg/kg). (B) Occupancy versus dose
measured at 1 h. Insert graph showed occupancy versus plasma exposure.
Results are expressed as average percentage receptor occupancy versus
vehicle treated rats ± SEM (n = 3).
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TABLE 2 | Effects of the OX1R antagonist JNJ-54717793 on sleep parameters in rats.
NREM latency REM latency NREM duration REM duration
Vehicle 31.8 ± 5.0 66.2 ± 2.1 55.0 ± 4.2 6.3 ± 1.2
JNJ-54717793 26.6 ± 3.2 47.3 ± 5.6∗ 59.5 ± 2.7 8.6 ± 1.2
The latency to NREM and REM sleep and the duration of NREM and REM sleep for the first 2 h period after injection (10 mg/kg s.c.) during the light phase are expressed
in minutes. Values represent mean ± SEM (n = 6). ∗p < 0.05 versus Vehicle as determined by paired Student’s t-test.
FIGURE 3 | Rapid eye movement (REM) sleep promoting effects of the OX1R antagonist JNJ-54717793 in OX2R KO mice. REM sleep latency and duration in OX2
KO mice (A,B) and wild-type (C,D) for the first 6 h period after oral dosing (30 mg/kg) during the light phase are expressed in minutes. Values represent the
mean ± SEM (n = 7 KO, n = 5 wild-type). ∗p < 0.05 and ∗∗p < 0.01 versus Vehicle as determined by paired Student’s t-test (latency) or two-way ANOVA followed
by Bonferroni post hoc test (duration).
Oral administration of JNJ-54717793 inhibited [3H]SB-
674042 binding to the rat tenia tecta, indicating sufficient
oral bioavailability and brain penetration. After acute oral
administration of 30 mg/kg, maximal OX1R occupancy was
observed at 15 min (87 ± 3%, Figure 2A) corresponding to a
plasma concentration of 3733 ± 440 ng/ml. The level of OX1R
occupancy remained above 58% for the first 6 h and then drop to
negligible level of occupancy.
For dose-dependency, ex vivo receptor occupancy was
measured 60 min after drug treatment (close to the Tmax,
observed in a rat pharmacokinetic study, result not shown). The
plateau for maximal OX1R occupancy (∼80 to 90%) was reached
at 3 mg/kg (Figure 2B) corresponding to a plasma concentration
of ∼310.6 ± 23.5 ng/ml. The ED50 was measured at 1.3 mg/kg
(corresponding to a plasma exposure of 84 ng/ml, 95% confidence
interval 26 to 277 ng/ml).
In vivo OX1R occupancy was also determined at various
time points following subcutaneous dosing of 10 mg/kg of
JNJ-54717793 (result not shown). Maximal OX1R occupancy
(83 ± 7%) was observed at 30 min. The plasma concentration
for maximal receptor occupancy was determined to be
2211 ± 339 ng/ml. At the 2 h time point, JNJ-54717793
still displayed 65% OX1R occupancy.
JNJ-54717793 Minimally Affects
Spontaneous Sleep in Rats
Rats were subcutaneously injected with the OX1R antagonist
JNJ-54717793 (10 mg/kg) at 2 h into the light phase. There
were no significant differences between JNJ-54717793 and
vehicle conditions (paired Student’s t-test) in most of the sleep
parameters examined over the 2 h period following the treatment.
Specifically, NREM sleep latency and duration were not altered.
REM sleep latency was slightly but significantly reduced without
producing a significant impact on REM sleep duration (Table 2).
Transient OX1R Blockade by
JNJ-54717793 Selectively Promotes REM
Sleep in OX2R Knockout Mice
Previous studies have demonstrated that OX1R antagonists
produce a disinhibition of REM sleep in the presence of OX2R
antagonism (Dugovic et al., 2014; Bonaventure et al., 2015b). In
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FIGURE 4 | Effect of JNJ-54717793 in a model of CO2 induced panic. Line graphs indicate the effects of oral gavage (p.o.) of vehicle, or 3, 10, or 30 mg/kg doses
of JNJ-54717793 on 20% CO2 induced changes (from 5 min baseline) in (A) mean arterial blood pressure (MAP, mm Hg), (B) heart rate (HR, beats/min, BPM), and
(C) general locomotor activity (counts/min) in freely moving rats surgically implanted with radiotelemetry probes. There were no significant differences in baseline
mean arterial blood pressure, HR, or locomotor activity (t-5 to t-1). Gray shaded area represents the 5 min CO2 or atmospheric air challenge, where atmospheric air
(RA) was also infused prior to and after for 5 min (also indicated at bottom of x-axis). ∗ Indicates between subjects differences using a Fisher’s LSD post hoc test that
was protected with a repeated measures ANOVA and an ANOVA at each time point, p < 0.05. Bar graphs indicate the effects of JNJ-54717793 on 20% CO2
induced changes in (D) social interaction (SI) in the SI test, and (E) line crossings and middle and center time in the open field test. ∗ and + respectively indicate
between subjects differences between veh/RA and veh/CO2 or veh/CO2 and 30 mg/kg JNJ-54717793/CO2 using a Fisher’s LSD post hoc test that was protected
with an ANOVA, p < 0.05.
the present study, the in vivo functional target engagement was
investigated in a model of permanent inhibition of OX2R, and
the effects of JNJ-5471773 on sleep-wake states were examined
in mice lacking the OX2R relative to their corresponding wild-
type mice. As compared to vehicle, oral dosing of JNJ-5471773
(30 mg/kg) at 2 h into the light phase to OX2R KO mice
significantly reduced the latency for REM sleep and prolonged
the time spent in REM sleep during the first 6 h post-treatment
(Figures 3A,B). In wild-type mice, JNJ-5471773 slightly reduced
REM sleep latency but did not alter REM sleep duration
(Figures 3C,D). NREM sleep latency and duration were not
affected in both genotypes (not shown).
Effect of JNJ-54717793 in a Model of
CO2 Induced Panic
Activation of the OX1R is a critical component of CO2-
mediated anxiety and hypertension (Johnson et al., 2012a).
Exposing rats to higher concentrations of hypercarbic gas
(e.g., 20% CO2) depolarizes OX neurons by interacting with
pH/ CO2 chemosensitive K+ channels (Williams et al., 2007),
and also causes subsequent release of orexin at post-synaptic
targets in the brain and spinal cord to mobilize anxiety-
like behavior, hypertension, and increases ventilatory responses
(Johnson et al., 2012c, 2015). JNJ-54717793 was tested in a rat
model of CO2-induced panic. JNJ-54717793 had no effect on
baseline cardiovascular activity (see t-5 to t-1 on Figures 4A,B).
The 30 mg/kg dose of JNJ-54717793 attenuated CO2-induced
pressor responses at multiple time points (3 mg/kg at one
time point) [treatment × time interaction F(56,462) = 4.5,
p < 0.001, n = 7,7,8,8,8/group, Figure 4A]. The 10 and
30 mg/kg dose of JNJ-54717793 attenuated CO2-induced
bradycardia responses at multiple time points [treatment × time
interaction F(56,462) = 8.8, p < 0.001, n = 7,7,8,8,8/group,
Figure 4B]. Although JNJ-54717793 had no effect on increases
in locomotor activity post CO2 (Figure 4C), the highest dose
attenuated/blocked CO2-induced anxiety behavior in the SI test
[F(3,38) = 3.5, p = 0.016, n = 7,7,8,8,8, Figure 4D] with no
apparent sedative effects (line crossings) in the open field test
[F(4,36)= 1.8, p= 0.150, n= 7,7,8,8,8, Figure 4E]. Nor was there
an effect on center or middle times [F(4,36)= 0.8, p= 0.512, and
F(4,36)= 1.7, p= 0.167, respectively].
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FIGURE 5 | In the 1-allyglycine (l-AG) panic vulnerability model experiment,
this illustration shows a representative coronal brain section of the
hypothalamus at –3.24 mm from Bregma taken from a Standard Stereotaxic
Rat Brain Atlas (Paxinos and Watson, 2005) with circles depicting unilateral
cannula placements and infusions of 1-allyglycine (a GABA synthesis inhibitor)
that were distributed from –3.24 to –6.70 mm from Bregma and located in the
perifornical and dorsomedial hypothalamic region or within ≤0.3 mm from
those regions. The illustration of the guide cannula depicts the target region
for cannula placements. 1-AG, 1-allyglycine; DA, anterior dorsomedial nucleus
of the hypothalamus; DMN, dorsomedial nucleus of the hypothalamus; f,
fornix; LH, lateral hypothalamus; mt, mammillothalamic fiber tract; PeF,
perifornical hypothalamic area.
Effect of JNJ-54717793 in a Model of
NaLac Induced Panic
The effect of JNJ-54717793 was investigated in a model
of panic vulnerability where chronic disinhibition of the
perifornical hypothalamic area orexin region leads to exacerbated
panic responses to a well-known interoceptive panicogenic
challenge (i.e., sodium lactate). The 1-allyglycine infusion
cannula placements were all located within the perifornical
and dorsomedial hypothalamic area from −3.24 to −3.60 in a
distribution consistent with prior 1-allyglycine studies in this
panic model (Johnson and Shekhar, 2006; Shekhar et al., 2006,
2011; Johnson et al., 2008, 2010, 2012b) (Figure 5), and also in
close proximity to orexin neuron distributions that are located
from−2.64 to−3.60 mm from Bregma (Peyron et al., 1998).
JNJ-54717793 had no effect on baseline cardiovascular activity
(see t-5 to t-1 on Figures 6A,B). Although there was no
treatment × time or overall treatment effect [F(3,29) = 2.8,
p = 0.090] detected, an individual ANOVA with post hoc test at
the t3 timepoint revealed an attenuation of pressor response with
the 10 mg/kg dose of JNJ-54717793 [F(3,32) = 3.3, p = 0.034,
n = 7,8,10,8, Figure 6A]. Compared to the vehicle group JNJ-
54717793 did not attenuate sodium lactate-induced tachycardia
[treatment × time interaction F(57,570) = 0.9, p = 0.780,
n = 7,8,10,9, Figure 6B]. JNJ-54717793 did not significantly
alter locomotion [treatment × time interaction, F(57,608) = 0.6,
p = 0.987, n = 8,9,10,9, Figure 6D], but the sodium lactate
also did not significantly increase locomotion [F(3,32) = 0.1,
p = 0.934]. Although JNJ-54717793 had minimal effects on
cardioexcitation, the highest dose did attenuate/block sodium
lactate-induced anxiety behavior in the SI test [F(4,40) = 5.1,
p = 0.002, n = 8,9,10,9, Figure 6C] with no apparent sedative
effects (line crossings) in the open field test [F(4,54) = 1.9,
p = 0.128, n = 11/group, Figure 6E]. Nor was there an effect
on center or middle times [F(4,54) = 0.9, p = 0.490 and
F(4,54) = 1.2, p = 0.340, respectively]. The unequal n’s/per
group were due to video malfunctions or complications with
radiotelemetry data acquisition.
DISCUSSION
In the present study we initially determined that JNJ-54717793
is a high affinity, potent and selective OX1R antagonist. After
systemic administration JNJ-54717793 crossed the blood brain
barrier, occupied OX1Rs in the rat brain and minimally affected
spontaneous sleep. We then utilized two different panic models
(i.e., threshold panic induction with 20% CO2 exposure in
normal rats and subthreshold panic induction with intravenous
sodium lactate infusion in panic-prone rats), and demonstrated
that pretreatment with JNJ-54717793 attenuated CO2 and
sodium lactate induced panic-like behaviors and cardiovascular
responses without altering baseline locomotor or autonomic
activity. These data are consistent with previous reports
of selective OX1R antagonists attenuating CO2 and sodium
lactate induced panic-associated behavior and cardiorespiratory
responses (Dias et al., 2010; Johnson et al., 2010, 2012d, 2015;
Bonaventure et al., 2015b) with little effect on sleep-wake states
(Dugovic et al., 2014). In contrast, benzodiazepines are also
panicolytic in these models, but do reduce locomotor activity
at panicolytic doses (Bonaventure et al., 2015b; Johnson et al.,
2015), which is consistent with sedative effects being a significant
side effect clinically (Charney and Heninger, 1985; Tesar and
Rosenbaum, 1986; Ballenger et al., 1988). In the 20% CO2 model,
a dual orexin receptor antagonist (i.e., DORA-12) has also been
shown to attenuate some aspects of the panic response, but
this appears to be primarily through the OX1R and not OX2R
since a highly selective and brain penetrant OX2R antagonist
(JNJ-10397049) did not alter panic responses to 20% CO2
(Bonaventure et al., 2015b; Johnson et al., 2015). In other stress
paradigms, both selective OX1R antagonists and selective OX2R
antagonists have been shown to have anxiolytic/panicolytic
effects. For instance, both OX1R and OX2R contribute to
cardiorespiratory responses post-perifornical hypothalamic area
disinhibition (Beig et al., 2015b), and both the OX1R antagonist
ACT335827 and the selective OX2R antagonist EMPA attenuate
novelty stress (cage changes) induced cardioexcitation (Beig et al.,
2015a). Yet, like benzodiazepines, selective OX2R antagonists
induce and prolong sleep in rodents (Dugovic et al., 2009; Mang
et al., 2012; Bonaventure et al., 2015a), thus making them less
ideal than selective OX1R antagonists. Collectively, these results
and previous data suggest that selective OX1R antagonists may
represent a novel approach of treating anxiety disorders, without
sedative effects.
Both panic models used here induce significant increases
in ex vivo cellular c-Fos activity within brain circuits strongly
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FIGURE 6 | Effect of JNJ-54717793 in a model of sodium lactate induced panic. Line graphs indicate the effects of oral gavage (p.o.) of vehicle, or 3, 10, or
30 mg/kg doses of JNJ-54717793 on intravenous sodium lactate (NaLac) induced changes (from 5 min baseline) in (A) mean arterial blood pressure (MAP, mm Hg),
(B) HR [beats/min (BPM)], and (D) general locomotor activity (counts/min) in freely moving rats surgically implanted with radiotelemetry probes. There were no
significant differences in baseline MAP, HR, or locomotor activity (t-5 to t-1 minute). Gray shaded area represents the NaLac infusions. ∗ Indicates between subjects
differences using a Fisher’s LSD post hoc test that was protected with a repeated measures ANOVA and an ANOVA at each time point, p < 0.05. Bar graphs
indicate the effects of JNJ-54717793 on NaLac induced changes in (C) SI in the SI test, and (E) line crossings and middle and center time in the open field test. ∗
and + respectively indicate between subjects differences between baseline and veh/NaLac or veh/NaLac and 30 mg/kg JNJ-54717793/NaLac using a Fisher’s LSD
post hoc test that was protected with an ANOVA, p < 0.05.
implicated in innate panic (and associated with panic attacks),
and in the panic vulnerability model there is also increase in
activity within fear associated learning centers (and associated
with strong phobia comorbidity with recurrent panic attacks). In
the 20% CO2 model in naïve rats, panic responses are associated
with increases in cellular activity within the perifornical
hypothalamic area orexin neurons and cardiorespiratory
brainstem circuits (Johnson et al., 2005, 2011, 2012d). In the
sodium lactate model, there are additional increases in cellular
responses within the amygdala and bed nucleus of the stria
terminalis (Johnson et al., 2008). Although orexin neurons
innervate many brain regions, they are particularly dense in these
brain regions that are mobilized in innate panic and learned
fear response (Peyron et al., 1998; Nambu et al., 1999). These
include noradrenergic locus coeruleus, and serotonergic systems
in midbrain raphe which are current therapeutic targets for
treating anxiety disorders, brainstem cardiorespiratory nuclei
and bed nucleus of the stria terminalis and amygdala. In many
brain regions both OX1R and OX2R receptors are significantly
expressed (Trivedi et al., 1998; Marcus et al., 2001). Yet in other
regions the expression is more limited to the OX1R or OX2R.
For instance, histaminergic neurons in the tuberomamillary
nucleus (TMN) have high expression of the OX2R and almost
undetectable expression of the OX1R (Eriksson et al., 2001;
Marcus et al., 2001). The TMN plays a critical role in wake
promotion (Bayer et al., 2001; Huang et al., 2001) and the OX2R
on TMN neurons is a major target for wake promoting properties
of OX neurons. Conversely, OX1R have a higher expression
within the limbic systems (bed nucleus of the stria terminalis
and amygdala), cingulate cortex, and noradrenergic locus
coeruleus. Accordingly, the functional significance is that OX2R
antagonists have potent sleep promoting effects (Bonaventure
et al., 2015a; Gotter et al., 2016), which are not apparent with
OX1R antagonists (Bonaventure et al., 2015b). Pretreating rats
with an OX1R antagonist prior to administering a panicogenic
drug (i.e., FG-7142) blocks FG-7142 induced increases in cellular
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activity in innate panic and learned fear brain circuits that have
higher expression of OX1R versus OX2R (e.g., amygdala and
dorsal periaqueductal gray and sympathetic nuclei) (Johnson
et al., 2012c). Taken together, the panicolytic effects of the OX1R
antagonist used here lends further support that OX1R antagonists
may be more effective than OX2R antagonists for treating anxiety
and fear associated disorders in the absence of sedative effects.
Although the orexin system and OX1Rs appear to be a novel
therapeutic target for treating anxiety symptoms/disorders, it is
important to note that orexin and orexin receptors may not be
involved in all stress responses. For instance, in addition to CO2
and sodium lactate challenges, OX neurons are activated during
arousal, exploration and footshock stress, but not by restraint
or cold exposure stress (Furlong et al., 2009). Furthermore,
in these same studies the dual orexin receptor antagonist
almorexant attenuated locomotor and cardiovascular responses
to exploration and footshock, but not to restraint or cold stress.
In mild stress paradigms, OX1R antagonists also do not alter
anxiety-associated avoidance behavior in the elevated plus maze
test or SI test (Yeoh et al., 2014). Yet, in more aversive stress
paradigms, OX1R antagonists do reduce anxiety/fear-associated
behaviors in the fear conditioned startle and in resident intruder
tests (Steiner et al., 2012, 2013). In other stress paradigms both
receptors are involved. Specifically, systemic administration of
selective antagonist at OX1R (ACT335827) or at OX2R (EMPA)
attenuates novelty stress (cage changes) induced cardioexcitation
(Beig et al., 2015a), and both OX1R and OX2R contribute to
cardiorespiratory responses post-perifornical hypothalamic area
disinhibition (Beig et al., 2015b).
Orexin receptor antagonists have also been implicated in
attenuation of fear-associated learning. For instance, in a cue
induced fear conditioning paradigm, Sears et al. (2013) reported
that OX enhances fear acquisition via OX1Rs and not OX2Rs
and through a locus coeruleus-amygdala pathway. This is
consistent with a study showing that systemic administration
of OX1R, but not OX2R antagonists also attenuate freezing
following contextual fear conditioning (Wang et al., 2017), and
another study demonstrating that following cue or contextual
fear conditioning, systemic or intra-amygdala administration
of an OX1R antagonist enhanced extinction, and intracebral
infusions of OXA impaired extinction (Flores et al., 2014). Yet,
in this study administration of an OX2R antagonist did enhance
contextual fear extinction while the orexin-B administration
had no effect. Pro fear circuits such as the central amygdala
and locus coeruleus are moderately and densely innervated
by orexin neurons, respectively (Peyron et al., 1998) with
the amygdala expressing more OX1R than OX2R and the
locus coeruleus expressing exclusively OX1R (Marcus et al.,
2001).
CONCLUSION
Although OX1R antagonists may not alleviate mild anxiety or
all anxiety associated symptoms they do appear to be effective
in rapidly reducing panic and fear associated responses in
most stress paradigms, especially as they become more severe,
without sedation side effects that would be associated with OX2R
antagonists or fast acting panicolytic benzodiazepines (Nutt et al.,
2002; Baldwin et al., 2005; Bandelow et al., 2008; Cloos and
Ferreira, 2009). OX1R antagonists also have an advantage over
SSRIs which become effective 2–3 weeks after daily use (Pollack
et al., 2007a,b) and tend to increase anxiety symptoms initially
both clinically (Goddard et al., 2001) and preclinically (Ravinder
et al., 2013).
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